Literature DB >> 7755163

The occurrence, virulence, and antimicrobial resistance of anaerobes in polymicrobial infections.

K E Aldridge1.   

Abstract

Polymicrobial aerobic/anaerobic bacterial infections occur frequently and have been documented in most anatomic sites in the body. The etiology of these infections is endogenous in that the normal microbial flora that colonize the various mucosal surfaces of the body can be isolated from these infections after trauma to these membranes allowing these organisms access to normally sterile sites. Subsequently, the organisms begin to proliferate, causing extensive tissue damage. These infections may spread to adjacent tissues or become loculated with abscess formation. In patients judged to have severe infection, surgery is often needed to debride the advancing spread of the infection, remove loculated pus, and reestablish sufficient blood flow to deliver appropriate antimicrobial agents to the infected site. Choice of antimicrobial agents should include agents with activity against both aerobes and anaerobes. Although a variety of anaerobes can be isolated from these infections, the Bacteroides fragilis group is the most clinically important group of anaerobes because of the production of virulence factors and the high incidence of beta-lactamase production. Against the various B. fragilis group species, metronidazole remains a very active agent, whereas resistance rates to clindamycin are high among the non-B. fragilis species. Because of the good activity of many cephalosporin/cephamycin agents against aerobic gram-negative bacteria and moderate to good activity against anaerobes, these compounds remain as broad-spectrum choices for use in therapy of mixed infections. The addition of beta-lactamase inhibitors (tazobactam, sulbactam, or clavulanate) to various beta-lactam agents has increased their antimicrobial spectrum against certain groups of aerobes, and particularly against beta-lactamase-producing anaerobes, including the B. fragilis group. The choice of single-agent therapy of mixed infections is ideally based on local data of susceptibility patterns of the various aerobes and anaerobes involved in these infections.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7755163

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  16 in total

1.  Inducible metronidazole resistance and nim genes in clinical Bacteroides fragilis group isolates.

Authors:  Sonja Löfmark; Hong Fang; Maria Hedberg; Charlotta Edlund
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Mixed Infections of the Paronychium with Prevotella bivia.

Authors:  Ather Mirza; Joseph J Bove; Joshua Litwa; Graham Appelbe
Journal:  J Hand Microsurg       Date:  2011-11-24

3.  In vitro susceptibilities of the Bacteroides fragilis group species: change in isolation rates significantly affects overall susceptibility data.

Authors:  Kenneth E Aldridge; Megan O'Brien
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model.

Authors:  L E Stearne; I C Gyssens; W H Goessens; J W Mouton; W J Oyen; J W van der Meer; H A Verbrugh
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

5.  Structural basis of the abscess-modulating polysaccharide A2 from Bacteroides fragilis.

Authors:  Y Wang; W M Kalka-Moll; M H Roehrl; D L Kasper
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

6.  Escherichia coli hemoglobin protease autotransporter contributes to synergistic abscess formation and heme-dependent growth of Bacteroides fragilis.

Authors:  Ben R Otto; Silvy J M van Dooren; Charles M Dozois; Joen Luirink; Bauke Oudega
Journal:  Infect Immun       Date:  2002-01       Impact factor: 3.441

7.  Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species.

Authors:  K E Aldridge; D Ashcraft; K Cambre; C L Pierson; S G Jenkins; J E Rosenblatt
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Bacteroides fragilis transfer factor Tn5520: the smallest bacterial mobilizable transposon containing single integrase and mobilization genes that function in Escherichia coli.

Authors:  G Vedantam; T J Novicki; D W Hecht
Journal:  J Bacteriol       Date:  1999-04       Impact factor: 3.490

9.  Association between the cfxA gene and transposon Tn4555 in Bacteroides distasonis strains and other Bacteroides species.

Authors:  Livia Q Ferreira; Katia E S Avelar; Jessica M B D Vieira; Geraldo R de Paula; Ana P V Colombo; Regina M C P Domingues; Maria C S Ferreira
Journal:  Curr Microbiol       Date:  2007-05-05       Impact factor: 2.188

10.  Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns.

Authors:  Kenneth E Aldridge; Deborah Ashcraft; Megan O'Brien; Charles V Sanders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.